0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover1564.18%IV-88.21%PremiumOct 18, 2024Expiry Date18.71Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9864Delta0.0011Gamma1.12Leverage Ratio-0.1568Theta0.0002Rho1.10Eff Leverage0.0007Vega
Catalyst Pharmaceuticals Stock Discussion
$Catalyst Pharmaceuticals (CPRX.US)$
eyooooooo
loading...
loading...
$Bristol-Myers Squibb (BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna (MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals (CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro...
Q1 Adjusted Net Income USD 46.8 Million Vs. Ibes Estimate USD 23.7 Million
Q1 Operating Income USD 27.1 Million Vs. Ibes Estimate USD 25.1 Million
Outlook FY Revenue USD 455-475 Million
No comment yet